Overview
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
Status:
Completed
Completed
Trial end date:
2012-09-01
2012-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world setting across two moderate RA cohorts: a Test Group of patients newly exposed to etanercept (Enbrel) therapy and a Control Group of patients with similar disease characteristics newly exposed to other, non-biologic therapies. 2. To assess the change over time (from baseline to the most recent follow-up) in the characteristics described at baseline in 2 British Society for Rheumatology Biologics Register (BSRBR) cohorts (i.e. moderate RA patients treated with Disease modifying anti-rheumatic drugs (DMARDs) alone versus moderate RA patients treated with Enbrel).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerTreatments:
Etanercept
Methotrexate
Criteria
Inclusion Criteria:The Test Group will be patients with rheumatoid arthritis, newly starting therapy with
etanercept (Enbrel). Inclusion criteria for the exposed cohort subjects are:
- Patients aged 18 years and over at the time of diagnosis;
- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);
- Patients who have given informed consent for long term follow-up and access to all
medical records;
- Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel)
for RA.
The Control Group:
- Patients aged 18 years and over a the time of diagnosis;
- Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);
- Patients who have given informed consent for long term follow-up and access to all
medical records; Patients are receiving at least one traditional DMARD and have never
been prescribed a biologic agent;
Exclusion Criteria:
Per BSRBR registry since data is retropsectively being analyzed